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Common variable immunodeﬁciency (CVID) is a heterogeneous group of inborn errors of
immunity characterized by reduced serum concentrations of different immunoglobulin
isotypes. CVID is the most prevalent symptomatic antibody deﬁciency with a broad range
of infectious and non-infectious clinical manifestations. Various genetic and immunological
defects are known to be involved in the pathogenesis of CVID. Monogenic defects
account for the pathogenesis of about 20-50% of CVID patients, while a variety of cases
do not have a deﬁned genetic background. Deﬁciencies in molecules of B cell receptor
signaling or other pathways involving B-cell development, activation, and proliferation
could be associated with monogenetic defects of CVID. Genetic defects damping different
B cell developmental stages can alter B- and even other lymphocytes’ differentiation and
might be involved in the clinical and immunologic presentations of the disorder. Reports
concerning T and B cell abnormalities have been published in CVID patients, but such
comprehensive data on monogenic CVID patients is few and no review article exists to
describe the abrogation of lymphocyte subsets in these disorders. Hence, we aimed to
review the role of altered B- and T-cell differentiation in the pathogenesis of CVID patients
with monogenic defects.
Keywords: inborn errors of immunity, primary immunodeﬁciency, common variable immunodeﬁciency disorder,
CVID, monogenic disorders, B cell subsets, T cell subsets

INTRODUCTION
Common variable immunodeﬁciency disorder (CVID) is the most prevalent symptomatic inborn
error of immunity (IEI) or primary immunodeﬁciency characterized by hypogammaglobulinemia,
impaired production of speciﬁc immunoglobulins (Igs) after vaccination and increased
susceptibility to infections (1). CVID is a complex and heterogeneous disease and the affected
patients present a wide spectrum of infectious and non-infectious clinical manifestations including
recurrent bacterial infections of various sites of the body particularly the respiratory tract,
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the PIK3R1 gene (APDS2), resulting in increased activity of the
PI3Kd pathway (43). The subsequent overactive PI3K
downstream signaling cascade (PI3K/AKT/mTOR signaling
pathway) is associated with abnormalities in B cell and T cell
differentiation in APDS mimicking CVID phenotype.
Regarding B cell subsets, an increased number of transitional B
cells in APDS patients has been demonstrated (7, 44). Given the role
of PIK3CD in human B cell development and differentiation in
bone marrow (BM), an overt function of PIK3CD could affect B cell
maturation and lead to the accumulation of peripheral immature
transitional B cells (9, 45, 46). In addition, it has been reported that
PI3Kd hyperactivation provokes the development of CD19+B220−
cells in mice which are considered equivalent to the expanded
transitional B cells in human APDS patients, because both cell types
produce interleukin 10 (IL-10). It is deemed that the increase of
these cells could be related to the increased susceptibility to S.
pneumonia infections observed in APDS patients. In addition to
transitional B cells, the counts of immature- and pre- B cells have
expanded in BM. However, the number of mature circulating B cells
has dramatically decreased. These data demonstrate an important
role of PIK3CD in early B cell development. On the other hand,
increased mature B cells could be due to a compensatory
mechanism in response to low B cell numbers. GOF mutations
could not only disturb B cell maturation but also disrupt the
production of normal memory B cells. Although the levels of IgG
and IgA are low in these patients, the IgM level could be normal,
indicating that both CVID and hyper IgM phenotypes are expected
in APDS. This immunophenotype is more frequent in the APDS2
group than in the APDS1 group (44).
In recent years, we and others investigated the responsiveness
of the PI3K pathway by assessing BCR-induced PI3K signaling in
CVID and APDS patients. We reported impaired pAkt
expression in a manner of BCR-induced PI3K signaling in Bcells of CVID patients (47). On the other hand, GOF in PIK3CD
or LOF mutations in PIK3R1 are associated with increased
phosphorylation of AKT in B cells of APDS patients (48, 49).
Given the similar phenotype of APDS and CVID patients,
evaluating the PI3K signaling could also help to delineate some
potential differences between them. A new study reported that
the presence of GOF mutations in PIK3CD does not impair BCRinduced AKT, mTOR and S6 phosphorylation, suggesting a
useful conﬁrmatory diagnostic test for APDS in the differential
diagnosis from other CVID patients (50).
Concerning T cell abnormalities in APDS patients, it has been
reported that more than 60% of the patients demonstrate CD4+
T cell deﬁciency. This reduction is more severe in APDS1 than in
APDS2 patients. Among T cell subsets, the profound deﬁciency
primarily affects naϊve CD4+ T cells. However, this scenario is
converse in CD8+ T cells, and a signiﬁcant increase is observed in
activated and effector memory CD8+ T cells in APDS patients.
Although APDS disorders are categorized as predominantly
antibody deﬁciencies (51, 52), abnormality in T cell subsets
arises some similarities with combined immunodeﬁciency
disorders. Affecting both B and T cells subsets in APDS
patients makes sense because the PI3K molecule acts
downstream of both BCR and TCR.

inﬂammatory complications, autoimmunity, interstitial lung
disease, enteropathy, granulomatous disease, atopic diseases,
lymphoproliferation and malignancy (1, 2).
In the majority of CVID patients, the exact pathogenesis
remains unknown and no cause for the immune defect has been
detected. In the past two decades, studies have revealed
monogenic causes leading to the CVID phenotype, however,
these monogenic causes account for the pathogenesis of almost
20-50% of the CVID cases (3). The clinical diagnosis of CVID is
an umbrella terminology covering several genetic defects, hence
monogenic disorders are now considered to be distinct
IEI entities.
Known genetic defects in CVID patients commonly involve
maturation, activation and survival of B cells. Hence, mutations
in genes encoding the receptors, activators and co-stimulators
involved in signaling, activation, survival, migration and
maturation of other lymphocytes, particularly T cells, are
associated with various degrees of impairment (4, 5). Based on
the mutated gene and affected molecule in the B- and T-cell
developmental pathways, immunological phenotypes vary
between patients with monogenic CVID and this could be
helpful in the diagnosis of these diseases.
Regarding identiﬁcation of B and T cell subsets in CVID
patients, we provided an overview on application of ﬂow
cytometry in primary antibody disorders (PAD) (including
CVID patients) described correct gating strategies along with
presenting some ﬂow cytometry examples of CVID patients to
guide the researchers for better identifying these cells (6).
Herein, we aimed to describe an updated review on the
impact of monogenic defects in alterations of B- and T-cell
subsets and their role in the pathogenesis of monogenic disorders
associated with the CVID phenotype. The affected genes and
molecules in these monogenic forms of CVID, their role and
mechanism of action in the B- and T-cell developmental pathway
and the subsequent abnormalities in B- and T-cell subsets will be
discussed in detail in the following sections. Tables 1, 2
summarize the main B- and T-cell abnormalities observed in
the majority of reported patients with monogenic CVID. Also,
the B- and T-cell developmental pathways with genes involved in
these processes are depicted in Figures 1, 2.

ACTIVATED PHOSPHOINOSITIDE
3-KINASE DELTA SYNDROME
Phosphoinositide-3-kinases (PI3Ks) are family members of the
intracellular downstream signaling transducer enzymes playing a
major role in the regulation of cellular functions of immune cells
like cell growth, proliferation, trafﬁcking, differentiation and
survival through conversion of phosphatidylinositol 3,4bisphosphate (PIP2) into active phosphatidylinositol 3,4,5triphosphate (PIP3) upon activation downstream of cytokine
receptors, B cell receptors (BCRs), T cell receptors (TCRs) and
Toll-like receptors (42). APDS is a recently described IEI caused
by heterozygous gain-of-function (GOF) mutations in the
PIK3CD gene (APDS1) or loss-of-function (34) mutations in
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TABLE 1 | B-cell subset abnormalities in monogenic CVID.
Genetic
defects

Stem
cell

Prepro-B

Pro-B Pre-B

PI3KCD
Gain-offunction
APDS1
PI3KR1
deﬁciency
APDS2
PTEN
deﬁciency
CD19
deﬁciency
CD81
deﬁciency
CD20
deﬁciency
CD21
deﬁciency
TACI
deﬁciency
BAFF-R
deﬁciency
TWEAK
deﬁciency
APRIL
deﬁciency
TRNT1
deﬁciency
NFKB1
deﬁciency
NFKB2
deﬁciency
IKAROS
deﬁciency
IRF2BP2
deﬁciency
ATP6AP1
deﬁciency
ARHGEF1
deﬁciency
SH3KBP1
deﬁciency
SEC61A1
deﬁciency
RAC2
deﬁciency
MOGS
deﬁciency
PI3Kg
deﬁciency
CTNNBL1
deﬁciency

↑

Immature
B

Transitional
B

Mature
B

Class-switched
memory B cell

Memory
B

↑

↑

↓

↓

↓

(7, 8)

↑

↓

↓

↓

(7, 9)

↓

↓

(10)

↓ / normal

↓

(11–
13)
(14)

↓

↓

Plasma
cell

↓

↓

↓

↑

↓

↓

↑CD21low

↓

↓

↑

↓/
normal
↓

↓ marginal zone B
cell
↓ marginal zone B
cell

↓

↓

↓

↓

↓
↓

↓marginal zone B
cell
↓marginal zone B
cell

↓
↓/
normal

↓/
normal
↓

normal /
↑

↑ marginal zone B
cell

↓

↓

↓

↓

↑

↓B cell plasmablasts
↓
↓marginal zone B
cell
↓mature naϊve
follicular B cells

↓
↓

↓/
normal
↑

↓

↓
↓

(25)
(26,
27)
(28)
(29)
(30,
31)
(32)

(34)
(35)
(36)

↓

↑

(16–
18)
(19–
21)
(22,
23)
(24)

(33)

↓
↓

Ref.

(15)

↓

↓

↓

Others

(37)
CD19+IgG+↓
CD19+IgA+↓
↓monocyte
↑eosinophil

(38)
(39)
(40)

APDS, activated phosphoinositide 3-kinase delta syndrome; PTEN, phosphatase and tensin homolog; CD, cluster of differentiation; TACI, transmembrane activator and calciummodulating cyclophilin ligand interactor; BAFF-R, B cell activating receptor; TWEAK, TNF-like weak inducer of apoptosis; APRIL, a proliferation-inducing ligand; TRNT1, transfer RNA
nucleotidyl transferase, CCA-adding 1; NFKB, nuclear factor-kappa-B; IRF2BP2, interferon regulatory factor 2-binding protein 2; ATP6AP1, ATPase H+ transporting lysosomal accessory
protein 1; ARHGEF1, Rho guanine nucleotide exchange factor 1; SH3KBP1, SH3-domain kinase-binding protein 1; SEC61A1, Sec61 translocon alpha 1 subunit; RAC2, Ras-related C3
botulinum toxin substrate 2; MOGS, mannosyl-oligosaccharide glucosidase; CTNNBL1, beta-catenin-like protein 1; ↓, decreased; ↑, increased; Ref, reference.

(FOXO1). Activation of FOXO1 by PTEN increases IgD BCR
expression leading to the production of mature B cells and
responsiveness to multivalent antigens. The germinal center is
the location of somatic hypermutation (SHM) and class switch
recombination (CSR). To produce high-afﬁnity antibodies of the

PTEN DEFICIENCY
Phosphatase and tensin homolog (PTEN) is a tumor suppressor
gene encoding PTEN (10). PTEN down-regulates PI3K/AKT
signaling by activation of the forkhead box transcription factor
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TABLE 2 | T-cell subset abnormalities in monogenic CVID.
Genetic

Stem

Early T

defects

cell

cell pro-

DN1

DN2

DN3

DN4

DP

CD4

Naϊve

Effector

Memory

CD4

CD4

CD4

CD8

Naϊve

Effector

Memory

CD8

CD8

CD8

↑

↑

Others

Ref.

genitor
↓

PI3KCD

(7,

Gain-of-

8)

function
APDS1
↓

PI3KR1

↓

↑

↑

(7,

deﬁciency

9)

APDS2
↓

PTEN

↓NK cell

(10)

deﬁciency
CD19

(11–

deﬁciency

13)

CD81

(14)

deﬁciency
CD20

(15)

deﬁciency
↑TEM

CD21

(16)

deﬁciency
TACI

(19–

deﬁciency

21)
↑NK cells

BAFF-R

(23)

deﬁciency
TWEAK

↑

↑

(24)

deﬁciency
APRIL

(25)

deﬁciency
↑

TRNT1

↑

↑

↓T follicular helper

(26)

↑gd T

deﬁciency
NFKB1

↓regulatory T cells

(28)

↓T follicular helper

(29)

deﬁciency
NFKB2

↓ NK function

deﬁciency
IKAROS
deﬁciency

↓/

normal

normal

/↑

↓regulatory T cells

(30,
31)

/↑
IRF2BP2

(32)

deﬁciency
ATP6AP1

(33)

deﬁciency
↓ Myeloid cell

ARHGEF1

(34)

deﬁciency
SH3KBP1

(35)

deﬁciency
SEC61A1

(36)

deﬁciency
↓

RAC2

↓

↓regulatory T cells

(37)

↓ T cell lymphoproliferative test

(38)

Central

↓NK cell, ↓TEMRA, ↓regulatory T cells,

(39,

and

↓CD3+ T cell, ↑DNabT cells, ↑CD4+HLA-

41)

effector↓

DR+ T cells

deﬁciency
MOGS
deﬁciency
PI3Kg

↓

↓

deﬁciency

(Continued)
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TABLE 2 | Continued
Genetic

Stem

Early T

defects

cell

cell pro-

DN1

DN2

DN3

DN4

DP

CD4

Naϊve

Effector

Memory

CD4

CD4

CD4

CD8

Naϊve

Effector

Memory

CD8

CD8

CD8

Others

Ref.

CTNNBL1

↓ regulatory T cells

(40)

deﬁciency

↑ T follicular helper-like T cells

genitor

APDS, activated phosphoinositide 3-kinase delta syndrome; PTEN, phosphatase and tensin homolog; CD, cluster of differentiation; TACI, transmembrane activator and calciummodulating cyclophilin ligand interactor; BAFF-R, B cell activating receptor; TWEAK, TNF-like weak inducer of apoptosis; APRIL, a proliferation-inducing ligand; TRNT1, transfer RNA
nucleotidyl transferase, CCA-adding 1; NFKB, nuclear factor-kappa-B; IRF2BP2, interferon regulatory factor 2-binding protein 2; ATP6AP1, ATPase H+ transporting lysosomal accessory
protein 1; ARHGEF1, Rho guanine nucleotide exchange factor 1; SH3KBP1, SH3-domain kinase-binding protein 1; SEC61A1, Sec61 translocon alpha 1 subunit; RAC2, Ras-related C3
botulinum toxin substrate 2; MOGS, mannosyl-oligosaccharide glucosidase; CTNNBL1, beta-catenin-like protein 1; ↓, decreased; ↑, increased; DN, double negative; DP, double positive;
Ref, reference.

and the development of the CVID phenotype (10). Analysis of a
CVID case with PTEN deﬁciency showed a decreased number of
class-switched memory B cells. Recurrent infections and
lymphadenopathy were among the clinical manifestations of
the aforementioned patient, which also have been seen
previously in the patients with decreased numbers of classswitched memory B cells (10, 55).
Regarding T cells, the PI3K pathway also plays a role in the
survival, proliferation, and motility of T cells. Hyperactivated

IgG, IgA, or IgE isotype, the development of GC reaction is
necessary. GC reaction is controlled by PI3K and FOXO1.
Furthermore, FOXO1 contributes to the localization of B cells
to the GC. Considering these processes, PTEN-deﬁcient B cells
are unable to produce sufﬁcient levels of IgA and IgG isotypes
due to abrogated regulation of PI3K (53). A study on mice
showed that B cell-speciﬁc PTEN-deﬁcient mice had a low level
of IgG and IgA (54). On the other hand, defects in PTEN could
be associated with abnormality in the count of memory B cells

FIGURE 1 | The development pathway of B cells and genes involved in each stage; mutation of these genes leads to monogenic CVID. RAC2 encodes a protein
that is involved in the differentiation of stem cells to pro-B cells, as well as pro-B cells to pre-B cells. Differentiation of pro-B cells to pre-B cells is further regulated by
proteins encoded by the IKZF1, PIK3R1, PIK3CD and TRNT1 genes. BAFFR and TWEAK encode proteins involved in differentiation of transitional B cells to naϊve
mature B cells. Then, naϊve mature B cells undergo selection and enter peripheral lymphoid tissues that is regulated by proteins encoded by the CD19, CD21,
CD81, SH3KBP1 and ATP6AP1 genes. TACI encodes a protein involved in conversion of naϊve mature B cells to germinal center B cells. CD20 encodes a protein
involved in conversion of naϊve mature B cells to extra follicular B cells. Finally, plasma cell differentiation is regulated by proteins encoded by the APRIL, RAC2,
IRF2BP2, SEC61A1, MOGS and CTNNBL1 genes.
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FIGURE 2 | The development pathway of T cells and genes involved in each stage; mutation of these genes leads to monogenic CVID. Conversion of early T cell
progenitor to double negative 1 (DN1) cells is regulated by the protein encoded by IKAROS, a transcription factor encoded by the IKZF1 gene, which later is involved
in conversion of stage double negative 4 (DN4) to stage double positive (DP). PTEN, NFKB1 and NFKB2 encode proteins involved in development of stage DN3 to
stage DN4. Then, RAC2 regulates differentiation of DP cells to single positive (SP) cells. Furthermore, NF-kB1 and NF-kB2 regulate the conversion of CD4+ cells to
naϊve CD4+ cells as well as CD8+ cells to naϊve CD8+ cells. The exact mechanism and location of action of proteins encoded by the PIK3R1, PIK3CD, TWEAK,
BAFFR, TRNT1, CD81, PI3Kg and CTNNBL1 genes are not understood and further studies are required to come to a deﬁnite conclusion.

PI3K pathway results from PTEN deﬁciency, interfering with the
normal development of T cells. PTEN-deﬁcient mice showed
increased thymic cellularity, autoimmunity, decreased
requirement for co-stimulation, and lymphoma. It may also
lead to a reduction in functional and mature NK T cells (56).

vaccination and hypogammaglobulinemia (11, 12). Given the
crucial role of CD19 expression in B cell differentiative including
the formation of B-1, germinal center, and marginal zone (MZ) B
cells as well as promoting the survival of naϊve recirculating B
cells, CD19 mutation is accompanied by the aforementioned B
cell subset abnormalities (58).
In vitro stimulation of CD19-deﬁcient B cells has shown
impaired antigen response with decreased serum IgG and IgA
levels and decreased to normal serum IgM levels (11, 12).
Moreover, these cells have the potential to undergo antigendependent differentiation and produce an antigen-selected Bcell–receptor repertoire, albeit with reduced efﬁciency (11, 12).
Contrary to what is expected, decreased serum IgG1 levels,
normal Ig response against protein vaccines and switched
memory B cell compartment were reported in a CD19deﬁcient patient (13).
Considering other lymphocyte subsets, no abnormalities are
observed in the number and function of T lymphocytes and NK
cells in CD19-deﬁcient patients.

CD19 DEFICIENCY
The cluster of differentiation 19 molecule (CD19), also known as
B-lymphocyte antigen CD19 is a transmembrane protein
exclusively expressed on B lineage cells and is encoded by the
CD19 gene (57). CD19 has an important role in the
differentiation and activation of B cells (57). CD19 in
conjunction with 3 other proteins -CD21, CD81 and CD225forms the B cell co-receptor complex, which upon antigen
encounter signals synergistically with the B-cell antigen
receptor and decreases the threshold for receptor-dependent
signaling (57). As a result, patients with mutations in the CD19
gene and low CD19 levels have a defective response of mature B
cells to antigenic stimulation.
Regarding B cell subsets, CD19-deﬁcient patients show a
normal number of mature peripheral B lymphocytes, decreased
number of CD27+ IgD + and CD27 + IgD - memory B cells,
defective SHM and CSR, impaired antibody response following
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Regarding T cell subsets, the number of CD3+, CD4+, CD8+ T
cells as well as CD16+56+ NK cells were reported to be within the
normal range (15).

crucial role in the trafﬁcking and compartmentalization of CD19
receptors on the surface of the B cells. As mentioned above,
CD19, CD21, CD81, and CD225, together, form a B cell coreceptor complex, and CD81, after encountering antigens, leads
to the assembly of the complex with BCR (59); decreased
threshold of antigen needed to induce B cell activation, clonal
expansion, and antibody production is the result of this
interaction (60). Impaired activation of B cells upon
stimulation, decreased CD19 expression, impaired and reduced
memory B cell, reduced transitional B cells, reduced plasma cell
formation is seen in patients with CD81 deﬁciency leading to the
development of hypogammaglobulinemia (decreased IgG,
normal IgM, and normal to low IgA) and CVID (14). The
affected patient may manifest symptoms of inﬂammatory
reactions and autoimmunity like thrombocytopenia associated
with antiplatelet antibodies. It seems that the CD19 complex has
a role in removing autoreactive B cell receptors; thus, CD19deﬁcient and CD81-deﬁcient patients could have a higher
frequency of autoreactive B cells than the normal
population (14).
Concerning T cells, CD81 is associated with CD4 and CD8
and co-engages with CD3 (T cell co-receptor), leading to the T
cell activation and differentiation to T helper (Th) 2 cells (14). It
seems that the association of immature thymocytes and CD81 on
stromal cells is required to induce early T cell development (61).
CD81 mainly co-stimulates primary human naïve T cells. CD81deﬁcient B cells are unable to induce a strong T cell response
(14). Nevertheless, the lack of CD81 on T cells does not alter the
proliferation or T cell response to antigen, and insufﬁcient T cellrelated responses are due to the impaired T-B cell
interaction (14).

CD21 DEFICIENCY
Complement receptor type 2 (CD21) encoded by the CR2 gene is
a member of the complement receptor protein family that
regulates complement activation. C3 fragments (i.e., C3d) are
the primary ligands of CD21 (64). Although some references
mention the contributing role of C3d in humoral immunity, it
seems that it is only accurate in mice and not humans (65). A
case of CVID with the absence of CD21 on B cells showed a
reduced number of class-switched memory B cells and
hypogammaglobulinemia (reduced IgG and IgA) (16). Another
patient with CD21 deﬁciency showed increased naïve mature B
cells and decreased memory B cells. Interestingly, the patient
showed a close to the normal frequency of SHM in memory B
cells (17). Moreover, two other siblings with CR2 mutation
showed decreased levels of class-switched memory B cells and
low to normal IgG (18). CD21 plays a role in antigen trapping in
B cell follicles (16). As previously mentioned, CD21 is associated
with CD81/CD19 complex and plays a role in lowering the
threshold needed to induce B cell activation and antigen
processing (64, 66). The function of CD21 is not as crucial as
the function of CD19 and CD81. An increased signaling
threshold may explain the increased memory cells, and it may
be restored by increased expression of CD19 (17).
CD21 is required for T-dependent antigen responses (66). It
also contributes to antigen presentation by facilizing the
internalization of immune complexes by B cells (64). We
expect to observe an increased number of CD21low B cells in
patients with CD21 deﬁciency. Also, an increased percentage of
CD21 low B cells is associated with autoimmunity and
splenomegaly (60, 67). Although CD21 has been detected in T
cells, its role in T cells is not completely understood (68). The
results of a study showed that T effector memory (TEM, CCR7CD45RA-) cells were increased in two siblings with CD21
deﬁciency (18). More studies are required to determine the
exact role of CD21 in T cells.

CD20 DEFICIENCY
The cluster of differentiation 20 molecule (CD20) encoded by the
CD20 gene (MS4A1) is a membrane-embedded surface
molecule expressed on B cells with a pivotal role in
transmembrane Ca 2+ transport required for the B cell
activation, proliferation, development, efﬁcient BCR signaling
and differentiation of B-cells into plasma cells (62).
To date, only one case of CD20 deﬁciency has been reported
(15). The index case had intact precursor B-cell differentiation in
the bone marrow with appropriate serum IgM levels and normal
total B-cell counts, but reduced circulating class-switched
memory B cells, decreased isotype switched Igs, and low IgG
antibody titers (15). In vitro assays showed a decreased frequency
of somatic hypermutations in IgG heavy chain genes and
impaired T cell-independent IgG antibody formation (15).
Moreover, an IgG against tetanus toxoid antigens could be
produced upon repeated booster immunization (15). In line
with the conserved function of CD20 in the generation of T
cell-independent antibody responses, CD20-deﬁcient mice had a
reduced ability to respond to T cell-independent antigens (15).
Also, T-dependent humoral immunity is found to be diminished
in CD20-null mice (63).

Frontiers in Immunology | www.frontiersin.org

TACI DEFICIENCY
Transmembrane activator and calcium-modulating cyclophilin
ligand interactor (TACI), also known as tumor necrosis factor
receptor superfamily member 13B (TNFRSF13B) is encoded by
the TNFRSF13B gene functioning as a cell membrane receptor
mainly expressed on the surface of B-cells and plasma cells (69).
The tuned function of TACI results in B-cell differentiation, upregulation of activation-induced cytidine deaminase (AID),
isotype CSR, and Ig production especially in a T-independent
manner (19, 69). TACI binds to its ligands “a proliferationinducing ligand” (APRIL) and “B cell-activating factor” (BAFF)
that signal through TACI, and activate several transcription
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factors including the nuclear factor of activated T cells (NFAT),
the activator protein 1 (AP1), and nuclear factor-kappa-B (NFkB) and ﬁnally induce CSR to IgA and IgG in naϊve B cells (70).
Thus, TACI deﬁciency is presumed to lead to reduced numbers
of class-switched memory B cells, loss of class switch and
ultimately hypogammaglobulinemia.
Regarding B cell subsets, patients with TACI mutations show
variable B cell phenotype, with normal or low numbers of B cells
(19–21). A proportion of patients have low class-switched memory
B cell numbers and low marginal zone cells (19–21). During the B
cell development, TACI plays an important role in B-1 cell
maintenance (71) as well as the B cell terminal differentiation into
plasma cells (72) leading to low serum IgG and IgA, normal to low
serum IgM based on the type of mutation and mono- or bi-allelic
defects of TACI (19–21). The affected patients also show poor
vaccination responses (19–21). Inappropriate levels of TACI
signaling may abolish immune regulation, subsequently inducing
autoimmune diseases, which is in agreement with the high
frequency of autoimmunity in TACI deﬁciency along with
susceptibility to infections of respiratory and gastrointestinal tracts
and lymphoproliferation (73).
Considering T cells, no major abnormalities have been
observed in T cell subsets and their proliferative responses in
TACI-deﬁcient patients (21).

can develop into the plasma cells (74). Antibody response to the
T-independent antigens is also impaired in patients with BAFFR deﬁciency (60) since IgM+ CD27+ marginal zone B cells are
mandatory for controlling infections with encapsulated
bacteria (74).
BAFF-R signaling also plays a role in the survival and
activation of T cells via the PI3K-AKT signaling pathway (75).
Based on an animal study, BAFF can increase CD3+CD4+,
CD4+CD25+, CD4+CD69+, and CD4+CD154+ T cells, and
decrease CD4+CD62L+ T cells (75).

TWEAK DEFICIENCY
TNF-like weak inducer of apoptosis (TWEAK), also known as
TNF ligand superfamily member 12 (TNFSF12) is a cytokine
belonging to the TNF ligand family encoded by the TNFSF12
gene (76). TWEAK is described as having a role in BAFF
signaling and B-cell survival (24). Hence, TNFSF12 mutations
are presumed to inhibit BAFF-dependent B-cell survival and
proliferation as well as Ig class switching through interaction
with BAFF and down-regulation of the non-canonical BAFFinduced NF-kB pathway.
To date, only one family with 3 cases has been reported with
TWEAK deﬁciency (24). Regarding B cells, the affected cases had
normal or reduced total B cells, class-switched memory B cells
numbers, impaired antibody responses to T-cell-dependent and
polysaccharide vaccines, and low levels of IgM, IgA, and IgG or
normal levels of IgG with low serum levels of IgG2 and IgG4
subclasses. As mentioned above, BAFF-mediated survival signals
are particularly critical during the transition between transitional
type 1 (T1) to type 2 (T2) immature B cell stage and loss of
BAFF-mediated survival signals such as TWEAK deﬁciency leads
to a block of B cell maturation at the T1 immature B cell
stage (77).
Concerning T cell subsets, a slightly increased percentage of
TCRab+CD4−CD8− T cells (double-negative T cells), increased
number of total T cells (especially CD8+ T cells) and normal level
of CD4+ T cells were observed in these patients (24). Animal
studies have revealed the critical role of TWEAK in attenuating
the transition from innate to adaptive TH1 immunity (78),
highlighting the correlation between TWEAK and CD8+ T cell
activation. However further studies are required to understand
the exact mechanism of TWEAK in the pathogenesis of T cell
subset abnormalities observed in TWEAK deﬁciency.

BAFF RECEPTOR DEFICIENCY
B cell-activating factor receptor (BAFF-R) belongs to the TNFreceptor superfamily encoded by the TNFRSF13C gene. While
immature B cells convert to transitional B cells, expression of the
BAFF-R inhibits premature cell death by receiving the prosurvival signaling. Warnatz et al. reported two siblings with
BAFF-R deﬁciency who developed CVID. They had decreased
levels of IgG and IgM but normal IgA. Their cell subset analysis
showed B-cell lymphopenia, reduced numbers of class-switched
memory B cells, and developmental arrest after the transitional
stage and before the cells became mature follicular B cells (22).
Another case with BAFF-R deﬁciency mimicked the symptoms
of Good syndrome, but immunologically presented severe
hypogammaglobulinemia (decreased IgG and undetectable IgM
and IgA), reduced numbers of class-switched memory B cells,
and increased NK cells. He had a normal proliferative T cell
response (23).
BAFF-R induces the PI3K pathway, which its role in B cell
development and proliferation has been previously discussed.
Evidence demonstrates that not all the B cell subsets require
BAFF signaling to survive or develop. It seems that follicular and
marginal zone B cells are highly dependent on BAFF signaling,
but B1 B cells (in mice, not humans) and switched memory B
cells can survive in the absence of BAFF signaling. Transitional 1
B cells are unable to differentiate into naïve and marginal zone B
cells in BAFF-R-deﬁcient patients. Moreover, the presence of
IgA+ plasma cells and increased IgA serum concentrations after
vaccination with T-dependent antigens in patients with BAFF-R
deﬁciency is another evidence of the fact that some B cells still
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APRIL DEFICIENCY
A proliferation-inducing ligand (APRIL), also known as TNF ligand
superfamily member 13 (TNFSF13) is a member of the TNF ligand
superfamily and is encoded by the TNFS13 gene (79, 80). APRIL
plays a pivotal role in inducing the differentiation of memory B cells
to plasma cells and immunoglobulin production. Thus, TNFSF13
mutations are presumed to be associated with impaired plasma cell
differentiation and immunoglobulin production. To date, only one
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frequent cause of monogenic CVID. Patients with this defect
manifest hypogammaglobulinemia due to decreased switched
memory B cells, and diminished lymphocyte proliferation after
stimulation with B cell mitogens. It seems that the patients
usually have a normal response to T-dependent and Tindependent antigens (86).
Maturation of the B cells, T-independent antibody response,
B cell survival and differentiation, and CSR signaling pathways
are associated with NF-kB signaling. NF-kB protects lymphocyte
precursors from apoptosis. The NF-kB pathway is also crucial for
the survival of developing B cells in the spleen, and complete
deﬁciencies in its complex lead to arrest at or near T1 B cells to
T2 B cells step. As a consequence of the absence or decreased
levels of marginal zone B cells can be observed. B1 cells also
require NF-kB1 and NF-kB2 for their formation. Even activation
and differentiation of follicular B-cells require NF-kB signaling.
Additionally, NF-kB plays a role in the survival of activated B
cells mainly due to stimulation through BCR (87). Moreover,
BAFF-R signaling and TACI signaling activate the canonical NFkB1 pathway and non-canonical NF-kB2 pathway in B cells,
respectively, leading to the B cell development, survival, and
activation (28).
Regarding T cells, NF-kB1 plays a role in the activation and
proliferation of naïve T cells. Besides, NF-kB controls the
expression of cytokines in T cells, survival of T cells, and CD4
Th differentiation via antigen-presenting cell-dependent and Tcell intrinsic mechanisms. Differentiation of T helper 2 cells is
selectively regulated by NF-kB1 (87). Moreover, NF-kB plays a
role in regulatory T cell (Treg) generation since NF-kB1
deﬁciency leads to abrogated Tregs generation (87).

patient with APRIL deﬁciency has been reported (25). The index
case presented with normal total B cells, slightly decreased number
of class-switched memory B cells, markedly reduced level of plasma
cells, increased circulating marginal zone B cells and
hypogammaglobulinemia (25).
As mentioned above, interactions between APRIL and the B
cell surface TNF receptor superfamily (strongly BCMA and to a
lesser strength TACI) play crucial roles in B cell development,
differentiation and terminal maturation (25), thus patients with
APRIL deﬁciency will have difﬁculty in maintaining the lifelong
humoral immunity. In this regard, animal studies have also
shown the relation between APRIL and long-term
maintenance of memory B cells in animal models (81, 82).
Considering other lymphocyte subsets, no abnormalities were
observed in T lymphocytes, NK cells and monocytes of the
reported APRIL-deﬁcient case (25). However, an animal study
on APRIL-deﬁcient mice revealed increased numbers of CD4+
effector/memory T cells (83). Thus, further studies with more
APRIL-deﬁcient cases are required to understand the probable
role of APRIL in development of other lymphocyte subsets.

TRNT1 DEFICIENCY
TRNT1 gene encodes transfer RNA (tRNA) nucleotidyltransferase,
CCA-adding 1 (TRNT1) protein adds CCA terminus to the 3-prime
end of tRNA precursors. This process is necessary for the
participation of tRNAs in protein biosynthesis (26). As seen in
several reports, TRNT1 deﬁciency leads to sideroblastic anemia with
B cell immunodeﬁciency, periodic fever, and developmental delay
(SFID syndrome) (27). Immunophenotyping of the patient with
TRNT1 gene mutation showed increased CD8+ cells, CD4+
terminally differentiated effector memory helper T lymphocytes
(CD4+ TEMRA), and CD4+ effector memory lymphocytes. In these
patients, T follicular helper cells and switched memory B cells were
reduced, and B-cell maturation in bone marrow was blocked at the
CD19+CD10+CD20+/− pre-B-cell stage (26, 84). To the best of our
knowledge, the exact mechanism of TRNT1 deﬁciency leading to
the development of CVID is not completely understood, but B cell
deﬁciency may be due to the increased endoplasmic reticulum (ER)
stress response (similar to activated T cells) (84). This hypothesis
should be investigated in future studies

NFKB2 DEFICIENCY
The nuclear factor NF-kappa-B p100 subunit (NF-kB2) plays the
main role in the non-canonical pathway of NF-kB encoded by
the NFKB2 gene. Patients with NFKB2 mutation showed reduced
numbers of switched memory and marginal zone B cells,
hypogammaglobulinemia, and weak antibody response to
antigens. Decreased number of T follicular helper cells,
impaired NK cell function, and severe B-cell deﬁciency were
also reported in some cases (29).
It seems that the non-canonical NF-kB pathway plays a major
role in the B cell maturation and survival in mice (88). Similar to
NF-kB1, NF-kB2 deﬁciency can lead to arrest at or near the T1 to
T2 differentiation step and, therefore, the absence of marginal
zone and follicular B cells. NF-kB2 deﬁciency can also diminish
B1 cells (87).

NFKB1 DEFICIENCY
NF-kB is a family of transcription factors consisting of 5 subunits
with pivotal roles in the development, survival, and activation of
B lymphocytes (85). NFKB1 gene encodes nuclear factor-kappaB p105 subunit (NF-kB1), and is almost present in all the cell
types of the human body. NF-kB1 plays a major role in different
pathways, including cell survival, inﬂammation, cell growth, and
stress responses. Together with other subunits, the NF-kB
complex regulates the expression of several target genes, such
as cytokines, chemokines, growth factors, apoptosis regulators,
receptors, etc. (28). Monoallelic mutation in NFKB1 is the most
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IKAROS DEFICIENCY
DNA-binding protein IKAROS (also known as Ikaros family
zinc ﬁnger protein 1) is a member of a family of hematopoietic
zinc-ﬁnger transcription factors encoded by the IKZF1 gene and
is involved in gene expression via chromatin remodeling (30).

9

June 2022 | Volume 13 | Article 912826

Fekrvand et al.

B and T Abnormalities in Monogenic CVID

related genes. The presence of IRF2BP2 decreased the
production of interleukin (IL)-2 and IL-4 by CD4+ T cells (96).
IL-2 induces plasma cell differentiation. Therefore, IRF2BP2
deﬁciency could impair antibody production and B cell
development via this mechanism mimicking a CVID phenotype.

IKAROS is a regulator of immune cells development and
differentiation, mainly in early B cells and CD4+ T cells. This
protein functions in the speciﬁcation and maturation of the T
lymphocyte as well as CD4 versus CD8 lineage differentiation
(89–91). This molecule is also required for the development of
the earliest B cell progenitors and at later stages of B cell
development during VDJ recombination in class switching of
the antibody isotypes and B cell receptor expression (92). Thus,
mutations in IKZF1 and dysfunctional IKAROS are presumed to
affect the expression of BCR in B cells leading to deregulation of
the BCR signaling during B cell development,
low proliferation rate and increased apoptosis of the B cells.
IKAROS binds many genes required for BCR signaling, Ig
recombination, cell growth and proliferation and acts as an
important transcription factor in pre-B cell differentiation (93).
Patients with haploinsufﬁciency of IKAROS deﬁciency show a
low to a normal number of total and memory B cells along with a
marked decrease in at least two of the three major Ig isotypes
(IgG, IgM, and IgA), demonstrating a defect in IKAROS
involving B cell development in the bone marrow. On the
other hand, IKAROS controls triggering and isotype selection
during CSR by controlling epigenetic marks and the
transcription process at constant region gene promoters (92).
Thus, the whole B cell development process from pro-B cell to
switched memory B cells should be considered in the patients.
Considering T cell subsets, these patients have normal to an
increased number of total T cells, low, normal or increased
number of CD4+ T cells, normal to an increased number of CD8+
T cells, reversed CD4/CD8 ratios with increased CD8+ T cells,
reduced regulatory T-cell counts and normal in vitro T cell
proliferation responses (30, 31). During the T cell development
pathway, IKAROS controls the differentiation of T cells and
development by the intensiﬁcation of pre-TCR and TCR (94). It
also functions in regulating negative selection as well as CD4
versus CD8 lineage development in the thymus (95). Of note,
dominant-negative mutations of IKZF1 are associated with a lack
of memory T cell generation and can develop the combined
immunodeﬁciency phenotype.

ATP6AP1 DEFICIENCY
ATPase H+ transporting lysosomal accessory protein 1
(ATP6AP1) is encoded by the ATP6AP1 gene and is an
accessory subunit of the vacuolar H+ -ATPase protein pump
that is required for luminal acidiﬁcation of secretory vesicles
(97). ATP6AP1 deﬁciency is a subclass of congenital disorders of
glycosylation (CDG) and is characterized by N- and Oglycosylation defects manifesting with immunodeﬁciency,
hepatopathy and cognitive impairment (33).
ATP6AP1-deﬁcient patients display hypogammaglobulinemia;
also some of the patients are reported to respond very poorly to
childhood vaccination (33, 98). Moreover, two patients were
reported to have high-normal levels of naϊve B cells and decreased
the number of switched memory B cells, suggesting a problem in
terminal B-cell differentiation (33).
The exact mechanism of ATP6AP1 in the pathogenesis of
CVID is unknown and requires further studies. ATP6AP1 is
reported to be involved in B cell differentiation, antigen
processing and antibody production via acidiﬁcation,
m e m b r an e t r a fﬁc kin g a n d fu si on eve nts (99–102).
Furthermore, several membrane-bound proteins involved in Bcell activation such as CD19 and CD40 are glycosylated, and
proper detection of antigens and Ig production require
fucosylated IgG-BCR (99). Therefore, a glycosylation defect
such that observed in ATP6AP1 deﬁciency might affect B-cell
activation and antibody production. Altogether, mutant
ATP6AP1 could affect B-cell activation and/or function leading
to decreased levels of Igs and recurrent infections (33).
To date, no studies have been reported regarding the role of
ATP6AP1 in T cell homeostasis and further investigations are
required to evaluate the possible T cell subset abnormalities in
patients with ATP6AP1 deﬁciency.

IRF2BP2 DEFICIENCY
Interferon regulatory factor 2-binding protein 2 (IRF2BP2) is
encoded by the IRF2BP2 gene and belongs to a family of proteins
that regulate transcription of type I interferon (IFN I) and
proteins downstream to IFN I and IFN II (32). Mutation in
the IRF2BP2 gene in several patients showed impaired
development of B cell plasmablasts. Although the patients had
a normal total B cell count, their switched memory B cells were
reduced. They also had decreased or undetectable serum levels of
IgM, IgA, and IgG2. Autoimmune diseases, such as type I
diabetes mellitus, were also present in some of the members of
the family with IRF2BP2 mutation (32).
IRF2BP2 represses the NFAT family by interacting with the
C-terminal domain of NFAT1. NFAT family plays a major role
in the regulations of cell cycle-, differentiation-, and apoptosis-
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ARHGEF1 DEFICIENCY
Rho guanine nucleotide exchange factor 1 (ARHGEF1) protein
belongs to the guanine nucleotide exchange factor (GEF) family
encoded by the ARHGEF1 gene. ARHGEF1 regulates proteins of
the RAS superfamily and RhoA guanosine triphosphatases
(GTPase). Lymphocytes with ARHGEF1 gene mutation showed
low RhoA activity and low cortical F-actin polymerization (34).
The regulation of actin cytoskeleton dynamics, conﬁning PI3K/
AKT signaling, and restricting B lymphocytes and myelocytes are
attributed to ARHGEF1 function (34). Patients with mutation in
the ARHGEF1 gene had an increased frequency of transitional B
cells, decreased marginal zone and memory B cells, impaired
antibody production in response to T-dependent and T-
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independent antigens, and germinal centers with small sizes
(which is associated with impaired function and development
of B cells). They also had impaired actin polymerization and,
consequently, impaired B and T cell migration. Immature
myeloid cells were also present in the blood sample of the
patient (34). Inability to suppress AKT activity is another
feature of cells with ARHGEF1deﬁciency (103). The exact role
o f A R H G E F 1 i n th e p a t h o g e n e s i s o f C V I D n e ed s
more evaluation.

T-independent antigens. Although they had a normal count of Band T-cell subpopulations, their B cell could not normally develop
into plasma cells. These mutations led to a lower antibody
production capacity, decreased plasma cell survival, impaired cotranslational protein translocation, and impaired Ca2+ homeostasis.
In vitro stimulation of B cells showed the patients carrying SEC61A1
mutation have impaired differentiation of peripheral B cells to
CD27+CD38high plasmablasts and CD38highCD138+ plasma cells
(36). This data demonstrates that SEC61A1 mutation high probably
inﬂuences B cell subsets with late differentiation such
as plasmablasts.

SH3KBP1 (CIN85) DEFICIENCY
SH3-domain kinase-binding protein 1 (SH3KBP1) also known as
CBL-interacting protein, 85-kD (CIN85) is encoded by the
SH3KBP1 gene. This protein is an adaptor protein with
multiple functions including vesicle trafﬁcking, cytoskeleton
remodeling, and ubiquitinoylation-dependent activation is
required for downregulation of BCR signaling (104). Mutant
SH3KBP1 is associated with intrinsic defects in BCR-mediated
activation and antibody production. In vitro studies have shown
speciﬁc defects in the canonical activation of NF-kB and upregulation of NF-kB-mediated activation markers CD86 and
intercellular adhesion molecule (ICAM)–1 in response to
stimulation of the BCR suggesting the nonredundant functions
of CIN85 for humoral immune responses (35).
To date, only two patients with SH3KBP1 deﬁciency have been
reported; these patients displayed normal numbers of B-cell subsets
including transitional, naϊve, memory B cells and plasmablasts, but
a decrease in IgM+IgD+ memory, IgM only memory, IgG switched
memory and IgA switched memory B cells as well as low serum
levels of IgM, IgG (total IgG or some of IgG subclasses) and/or IgA,
impaired response to polysaccharide vaccination (35). CIN85 is a
key component of the BCR-associated process needed for the
initiation and continuation of antigen defection signal
transduction. It is also required for normal development or
maintenance of the B-1a B cell compartment with mutant CIN85
leading to reduced numbers of mature B cells (105).
Regarding T cell subsets, CD3+, CD4+, CD8+, regulatory and
memory CD8+ T cells were all reported to be normal in number
(35). The physiological function of CIN85 in T cells is still
unknown and more studies are required to further evaluate T
cell subset abnormalities in SH3KBP1-deﬁcient patients.

RAC2 DEFICIENCY
Ras-related C3 botulinum toxin substrate 2 (RAC2) is a GTPase
and member of the Rac subfamily of the family “Rho family of
GTPase” exclusively expressed on hematopoietic cells and is
encoded by the RAC2 gene (106). Members of the Rho family of
GTPases are a group of cellular signaling molecules binding
downstream effectors to regulate a diverse array of cellular
events, including the control of cell growth, cell cycle, actin
cytoskeleton reorganization, gene transcription and the
activation of protein kinases (107).
Mutations in the RAC2 gene have been reported in several patients
with various forms of IEI indicating mutations in the same gene may
affect the immune system variably. For example, autosomal
dominant-negative (34) RAC2 mutations have been reported in
patients with phagocytic immunodeﬁciency with preferentially
affected granulocytes (108–110), while autosomal-dominant
activating (GOF) mutations of RAC2 are reported to lead to
combined immunodeﬁciency (111–113) or severe combined
immunodeﬁciency (SCID) (114) and have a prevalent effect on T
lymphocytes. Furthermore, a recent study has reported two patients
with the autosomal recessive LOF mutation, who had characteristics
of CVID and showed modest alterations in primary and secondary
neutrophilic granules associated with chemotactic defects and a
milder immunologic phenotype than those with autosomal
dominant RAC2 mutations (37). Considering B cell subsets, the
RAC2-deﬁcient patients with CVID phenotype displayed a reduced
to a normal percentage of B lymphocytes, reduced serum level of IgG,
IgA and IgM and poor response to polysaccharide vaccination (37).
In vivo animal studies on Rac2−/− mice have revealed peripheral blood
B lymphocytosis with marked reductions in B1a and marginal zone B
lymphocytes along with hypogammaglobulinemia suggesting a
deﬁciency in BCR-mediated signaling and B cell development in a
Rac2-dependent manner (115). Another murine study also suggested
a critical role of RAC2 in BCR signal transduction-associated upregulation of BAFF-R as a key survival molecule required for B cell
development and maintenance (116).
Regarding T cell subsets, the RAC2-deﬁcient patients with
CVID phenotype show decreased percentages of naϊve CD4+ and
CD8+ T cells, reduced percentage of regulatory T cells and
slightly low CD4/CD8 ratio (37). RAC2 plays a critical role
during multiple stages of T-cell development by regulating
survival and proliferation signals and Rac2-knockout mice

SEC61A1 DEFICIENCY
Sec61 translocon alpha 1 subunit (SEC61A1) is one of the subunits
of the heteromeric SEC61 complex encoded by the SEC61A1 gene.
The SEC61 complex is a membrane channel located in the
membrane of the ER and facilitates the translocation of proteins
across ER membrane. ER development is one of the main steps of
differentiation of B cells to plasma cells since they are the main
producer of antibodies with high Er stress for rapid production of
massive Ig secretion (36). Patients with mutation in the SEC61A1
gene had low levels of IgG, IgM, and IgA with a lack of response to
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show reduced immature CD4+CD8+ and mature CD4+ populations
in the thymus as well as CD4+ and CD8+ populations in the
spleen (117).

processing factor 19 (Prp19)- cell division cycle 5–like
(CDC5L) complex that forms an integral part of the
spliceosome and is required for activating pre-mRNA splicing
(40). Furthermore, CTNNBL1 is identiﬁed as an AID-interacting
protein through which it participates in SHM as well as CSR
(118). Thus, mutations in CTNNBL1 and regions in AID
required for CTNNBL1 interaction is presumed to yield
diminished Ig hypermutation and class switching (118).
Approximately 20% of CVID patients develop autoimmune
cytopenias (16) following defective early B cell development and
the resultant autoreactive B cells that secret autoantibodies
targeting erythrocytes and/or platelets (1). Recently, a CVID
patient with autoimmune cytopenias (CVID+AIC) was found to
harbor a rare mutation in the CTNNBL1 gene (40). Regarding B
cell subsets, the patient showed decreased class-switched
memory B cells and hypogammaglobulinemia (40).
Considering T cell subsets, a decreased frequency of Tregs as
well as increased circulating T follicular helper–like (Tfh-like) T
cells were observed (40). However, further studies are required to
understand the possible role of CTNNBL1 in T lymphocyte
development pathway.

MANNOSYL-OLIGOSACCHARIDE
GLUCOSIDASE DEFICIENCY
MOGS gene encoding mannosyl-oligosaccharide glucosidase
plays a role in processing N-linked glycoproteins. It
particularly cleaves the distal alpha-1,2-linked glucose residue
in the Glc3Man9GlcNAc2 oligosaccharide precursor (38). A case
report of two patients with MOGS mutation showed normal B
cells and plasma cells. The patients had abnormal N-glycosylated
Igs; in vivo studies showed a lower half-life of IgG in comparison
with control cells that could be the underlying cause of
hypogammaglobulinemia. The patients also had impaired
antibody response to viruses with a glycosylated capsule.
Interestingly, the patients with MOGS mutation had no
recurrent or severe bacterial infection, and the underlying
reason is not completely understood (38).

B- AND T-CELL ABNORMALITIES IN NONGENETIC FORMS OF CVID

PHOSPHATIDYLINOSITOL 3-KINASEGAMMA
PI3Kg is encoded by PIK3CG gene and phosphorylates PtdIns(4,5)
P2 (Phosphatidylinositol 4,5-bisphosphate) to generate PIP3 (39).
The produced second messenger regulates many signaling cascades
related to cell survival, growth, proliferation, and motility, as well as
cellular responses to growth factors, cytokines, chemokines, and
antigen receptor stimulation (39). Although PI3Kg is mainly
known for its roles in myeloid cells, knockout (KO) mice show
impaired antibody response and T cells. PI3Kg is also involved in
TLR-related pathways (39). While T cells activate via PI3Kg and
PI3Kd, B cells mainly respond through PI3Kd; therefore,
we expect more T cell defects than B cell defects in PI3Kgdeﬁcient patients (41). A patient with mutated PI3Kg showed
pathological accumulation of T cells, autoimmune cytopenia,
hypogammaglobulinemia, thrombocytopenia, lymphopenias,
eosinophilia, lymphadenopathy, and splenomegaly. She had
decreased counts of CD8+ T cells, CD8+ central memory, CD8+
effector memory, CD8+ TEMRA, CD4+CD25+ T cells, NK cells,
monocytes, and memory B cells, and increased levels of DNabT
cells, CD4+HLA-DR+ T cells, and eosinophils. It seems that the
patients with PI3Kg deﬁciency have impaired response to TCR
stimulation (39). Another patient with PI3Kg deﬁciency had
thrombocytopenia, decreased number of lymphocytes, CD3+ T
cells, CD4+ T cells, and NK cells (41).

B- and T-cell subsets are also affected in non-genetic form of
CVID. We demonstrated a reduced levels of CD4+ T cells, Tregs,
and Th17 in one study on patients with CVID without known
monogenic disease; while the frequencies of Th1, Th1-like Th17,
and Th22 subsets were normal. It seems that infection and the
lymphoproliferative phenotype of the patients are associated
with the imbalance of Th17 and Tregs (119). In another study,
we evaluated both B and T cell subsets on genetically unsolved
CVID to show association of B and T lymphocyte abnormalities
with the incidence of CVID. We indicated reduced number of
total, naϊve, memory B cells and plasmablasts, decrease in
number of total, naϊve, central memory and regulatory CD4+ T
cells and naϊve CD8+ T cells as well as an increase in CD21low and
transitional B cells, effector memory and TEMRA CD4+ T-cell
subsets as well as total, effector memory, TEMRA, activated
and cytotoxic CD8+ T cells on genetically unsolved CVID
patients (120). Some novel correlations between lymphocyte
abnormalities observed only among patients without
monogenic defects and in the absence of any genetic defect
may hint toward genetically unsolved CVID. Reduced levels of
total and naive T cells and Tregs besides increased EM and
TEMRA T cells seem to have a direct impact on changes in B cell
subsets, but activated and cytotoxic CD8+ T cells indirectly
inﬂuence B cells alterations.

CTNNBL1 DEFICIENCY

CONCLUSION

Beta-catenin-like protein 1 (CTNNBL1) is encoded by the
CTNNBL1 gene and is a component of the pre-mRNA

Monogenic forms of CVID account for the pathogenesis of 2050% of CVID patients. Based on the normal function of the
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and almost distinct for most of the CVID patients with monogenic
defects, the affected patients could be timely diagnosed, also targeted
gene sequencing instead of whole-exome sequencing (WES) could
be implemented for the molecular dissection. Thus, this approach
will help for a rapid, cost-effective, time-saving diagnosis and is
critically important for the optimized treatment required for
improving the patients’ quality of life as well as accurate genetic
counseling in the affected families.

mutated gene in the development of the B and T cells, monogenic
CVID disorders display different immunophenotypes, including
changes in switched memory B cells, NK cells, plasma cells,
transitional B cells, follicular T helper cells, marginal zone B cells,
etc. that may even vary in patients with the same mutation. The
varied alteration of B- and T-cell subsets depends on the
maturational arrest of the B- and T-cell development. Since
there are only a few case report studies on different monogenic
CVIDs, attribution of speciﬁc clinical manifestations and their
frequency in the affected patients to a deﬁnite gene mutation
requires more investigations.
Overall, recurrent respiratory infections, chronic diarrhea,
splenomegaly, autoimmune diseases, thrombocytopenia
(immune-related), lymphadenopathy, glomerulonephritis, etc.,
are common in patients with monogenic CVID. Having a
comprehensive view of B- and T-cell subset alterations in
monogenic CVID and using the laboratory data that is speciﬁc
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